Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus

Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrient intake and elicits glucose-stimulated insulin secretion while suppressing glucagon secretion. It also slows gastric emptying, which contributes to decreased postprandial glycemic excursions. In the...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Young Min, Wideman, Rhonda D., Kieffer, Timothy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871042/
https://www.ncbi.nlm.nih.gov/pubmed/24396690
http://dx.doi.org/10.3803/EnM.2013.28.4.262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871042/
https://www.ncbi.nlm.nih.gov/pubmed/24396690
http://dx.doi.org/10.3803/EnM.2013.28.4.262

Ejemplares similares